GleamWall
中文EN

PROK PROKIDNEY CORP.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850270 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.2%
TTM net income YoY-45.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-24,830.3%
Net margin-13,326.7%
FCF margin-21,655.0%
EBITDA margin-24,002.1%

Returns

ROE—
ROA-36.8%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets15.8%
Debt / equity—
Current ratio5.04x
Interest coverage-10,690.83x

Cash quality & payout

Operating cash flow / net income1.48x
Accruals ratio17.8%
Payout ratio—
Capex / revenue1,884.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$174,000$150,000$226,000$225,000$217,000$221,000$230,000$76,000
R&D expense$40.84M$36.09M$33.84M$34.16M$26.82M$25.88M$27.26M$39.78M
SG&A expense$13.09M$12.43M$11.32M$11.44M$11.94M$14.05M$14.36M$11.87M
Operating income-$53.76M-$48.37M-$44.93M-$45.37M-$38.54M-$39.71M-$41.39M-$51.57M
Interest expense$1,000$1,000$15,000$1,000$2,000$1,000$0$2,000
Pretax income-$52.23M-$46.44M-$42.62M-$42.44M-$35.28M-$36.12M-$37.36M-$46.78M
Income tax-$436,000$0$0-$1.58M$560,000$848,000$591,000$1.70M
Net income-$35.59M-$28.42M-$20.04M-$19.23M-$16.47M-$16.55M-$16.73M-$21.28M
EBITDA-$52.28M-$46.92M-$43.27M-$43.53M-$37.14M-$38.22M-$39.79M-$50.00M
EPS (diluted)————————
Balance sheet
Cash & equivalents$81.36M$74.87M$101.89M$108.54M$95.32M$84.94M$97.81M$99.12M
Current assets$151.45M$189.77M$234.90M$280.68M$299.99M$324.44M$359.66M$395.88M
PP&E, net$55.81M$56.04M$54.44M$51.23M$47.75M$43.52M$43.33M$42.22M
Total assets$210.28M$249.02M$292.78M$335.57M$351.61M$372.13M$406.06M$441.07M
Current liabilities$30.04M$22.71M$25.93M$30.74M$29.06M$28.26M$32.81M$36.22M
Total liabilities$33.30M$26.18M$29.68M$34.78M$33.27M$32.68M$36.08M$39.44M
Shareholders' equity-$906.85M-$883.53M-$1.02B-$1.01B-$1.01B-$1.00B-$998.55M-$994.95M
Cash flow statement
Operating cash flow-$38.65M-$40.37M-$41.68M-$32.51M-$26.60M-$31.42M-$29.59M-$24.17M
Capital expenditure$1.23M$3.83M$3.79M$5.75M$5.20M$3.11M$1.14M$25.51M
Free cash flow-$39.88M-$44.21M-$45.47M-$38.27M-$31.79M-$34.53M-$30.73M-$49.68M
Investing cash flow$45.09M$12.81M$34.83M$28.09M$29.02M$18.57M$28.29M$15.08M
Financing cash flow$48,000$541,000$215,000$17.63M$7.96M-$14,000-$12,000$123,000
Depreciation & amortization$1.48M$1.45M$1.66M$1.84M$1.40M$1.49M$1.60M$1.57M
Stock-based compensation$5.88M$5.59M$4.95M$5.70M$6.67M$6.54M$6.42M$6.95M

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.